EGF and non-small cell lung carcinoma: Furthermore, Song et al. [180] demonstrated that epidermal growth factor-modified docetaxel and RES co-encapsulated lipid-polymeric hybrid NPs (EGF DTX/RSV LPNs) significantly inhibited the viability and proliferation of HCC827 and NCIH2135 non-small cell lung cancer cells (NSCLCs) compared to DTX/RSV LPNs or free DTX/RSVDTX.